Invenomic Capital Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$5.3M |
| 2 |
Dollar Tree
DLTR
|
+$5.02M |
| 3 |
Immersion
IMMR
|
+$4.97M |
| 4 |
McKesson
MCK
|
+$4.21M |
| 5 |
Popular Inc
BPOP
|
+$3.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teck Resources
TECK
|
+$3.41M |
| 2 |
Lockheed Martin
LMT
|
+$3.38M |
| 3 |
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
|
+$3.27M |
| 4 |
NewMarket
NEU
|
+$2.22M |
| 5 |
Lazard
LAZ
|
+$2.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.96% |
| 2 | Consumer Discretionary | 13.29% |
| 3 | Materials | 11.69% |
| 4 | Industrials | 11.21% |
| 5 | Healthcare | 8.37% |
Similar funds
Invenomic Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Invenomic Capital Management held 155 positions worth $308M, down 26% from $418M the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Invenomic Capital Management withdrew a net $101M in Q3 2021, closing 36 positions and reducing 13 holdings. Its most notable exit was Lockheed Martin, an estimated $3.38M position sold in full.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 9.1% a quarter earlier, followed by Consumer Discretionary and Materials.
Against the trend, Invenomic Capital Management opened a new position in Alibaba worth $4.31M.
- Invenomic Capital Management's largest Q3 2021 buy was Alibaba: 29,138 shares worth $4.31M.
- Invenomic Capital Management added most to Immersion in Q3 2021, an estimated $4.97M increase.
- Invenomic Capital Management's biggest Q3 2021 reduction was Teck Resources, cutting an estimated $3.41M.
- Invenomic Capital Management fully exited Lockheed Martin in Q3 2021, selling an estimated $3.38M.
- Invenomic Capital Management's ten largest holdings make up 28% of its $308M portfolio in Q3 2021.
- Invenomic Capital Management opened 31 new positions and closed 36 in Q3 2021.
- Invenomic Capital Management's portfolio value fell 26% quarter-over-quarter to $308M.
Based on Invenomic Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.